Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC $MGTX

Johnson & Johnson purchased a new position in MeiraGTx Holdings PLC (NASDAQ:MGTX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,641,064 shares of the company’s stock, valued at approximately $89,720,775,000. MeiraGTx accounts for approximately 11.2% of Johnson & Johnson’s investment portfolio, making the stock its 3rd largest holding. Johnson & Johnson owned about 7.17% of MeiraGTx at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in MeiraGTx by 43.8% during the second quarter. BNP Paribas Financial Markets now owns 4,810 shares of the company’s stock valued at $31,000 after buying an additional 1,466 shares during the period. Kennedy Capital Management LLC lifted its holdings in MeiraGTx by 2.2% during the fourth quarter. Kennedy Capital Management LLC now owns 70,738 shares of the company’s stock worth $562,000 after buying an additional 1,495 shares during the period. Russell Investments Group Ltd. boosted its position in MeiraGTx by 4.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 82,844 shares of the company’s stock valued at $682,000 after acquiring an additional 3,452 shares in the last quarter. XTX Topco Ltd boosted its position in MeiraGTx by 11.0% during the 4th quarter. XTX Topco Ltd now owns 38,030 shares of the company’s stock valued at $302,000 after acquiring an additional 3,766 shares in the last quarter. Finally, Hsbc Holdings PLC increased its holdings in shares of MeiraGTx by 24.3% in the 4th quarter. Hsbc Holdings PLC now owns 23,792 shares of the company’s stock valued at $189,000 after acquiring an additional 4,649 shares during the period. 67.48% of the stock is currently owned by institutional investors.

More MeiraGTx News

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: RBC raised its price target to $27 from $26 and maintained an “outperform” rating. The new target implies substantial potential upside from the reported $13.52 trading level, providing a bullish signal from a major analyst. Benzinga
• Positive Sentiment: MeiraGTx reported second-quarter EPS of $1.71, significantly exceeding consensus expectations for a loss. Revenue reached $321.43 million versus an analyst estimate of approximately $0.70 million, and the company swung to a quarterly profit from a year-earlier loss. The magnitude of the beat is likely a key driver of the stock’s advance, though investors may assess how much of the results reflects recurring operations versus nonrecurring items. MeiraGTx Swings to Q2 Profit, Revenue Rises
• Positive Sentiment: The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 AQUAx data for radiation-induced dry mouth. It also acquired rights to bota-vec for X-linked retinitis pigmentosa and expects global regulatory filings in 2026, with a potential AAV2-hAQP1 BLA filing in mid-2027. MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
• Neutral Sentiment: A comparison of MeiraGTx with Biomea Fusion provides sector context but does not introduce a new company-specific catalyst. Head-To-Head Survey: Biomea Fusion and MeiraGTx
• Negative Sentiment: MeiraGTx funded the bota-vec acquisition with a $100 million equity financing, which may create shareholder dilution. However, the transaction also includes up to $400 million of strategic investment, including as much as $375 million in non-dilutive capital.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Zacks Research raised MeiraGTx from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Piper Sandler raised their price objective on MeiraGTx from $26.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of MeiraGTx in a research note on Wednesday, July 8th. Royal Bank Of Canada lifted their target price on MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Wall Street Zen upgraded shares of MeiraGTx from a “hold” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $26.17.

MeiraGTx Trading Up 6.7%

NASDAQ MGTX opened at $13.52 on Friday. The firm’s fifty day simple moving average is $12.09 and its two-hundred day simple moving average is $9.82. The firm has a market capitalization of $1.25 billion, a P/E ratio of 19.04 and a beta of 1.23. MeiraGTx Holdings PLC has a 12-month low of $6.62 and a 12-month high of $15.35.

MeiraGTx (NASDAQ:MGTX) last issued its quarterly earnings data on Thursday, August 13th. The company reported $1.71 EPS for the quarter, beating the consensus estimate of ($0.46) by $2.17. MeiraGTx had a negative return on equity of 226.79% and a net margin of 19.87%.The firm had revenue of $321.43 million during the quarter, compared to analyst estimates of $0.70 million. As a group, sell-side analysts predict that MeiraGTx Holdings PLC will post -0.48 earnings per share for the current fiscal year.

Insider Activity at MeiraGTx

In other MeiraGTx news, insider Stuart Naylor sold 27,659 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $14.80, for a total value of $409,353.20. Following the completion of the sale, the insider directly owned 640,846 shares in the company, valued at approximately $9,484,520.80. This trade represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alexandria Forbes sold 62,000 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $9.17, for a total value of $568,540.00. Following the completion of the sale, the chief executive officer directly owned 1,387,695 shares of the company’s stock, valued at approximately $12,725,163.15. This represents a 4.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock valued at $1,678,453 in the last ninety days. Corporate insiders own 7.40% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.